Search: onr:"swepub:oai:gup.ub.gu.se/75031" >
A novel biodegradab...
-
Engstrand, Thomas
(author)
A novel biodegradable delivery system for bone morphogenetic protein-2.
- Article/chapterEnglish2008
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/75031
-
https://gup.ub.gu.se/publication/75031URI
-
https://doi.org/10.1097/PRS.0b013e31817151b0DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:117189115URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
BACKGROUND: The efficacy of recombinant growth factors in vivo is highly dependent on the delivery vehicle. The authors investigated the osteoinductive effects of recombinant human bone morphogenetic proteins (BMP)-2 implanted together with a complex of heparin and chitosan. METHODS: Sixty rats were used. Three different carriers in gel formulation (type I collagen, heparin/type I collagen, and heparin/chitosan) were mixed with either 0, 10, or 50 microg of BMP-2, making the number of groups nine. The gels were injected into the quadriceps muscles of both legs in 45 rats (n = 10 per group). Freeze-dried formulations of the carriers were also tested with the same amounts of BMP-2 using 15 rats (n = 5 per group). Four weeks after implantation, the quality and amount of newly formed bone were assessed. RESULTS: Chitosan was shown to protect the heparinase-mediated degradation of heparin in vitro. The osteoinductive effects of BMP-2 in combination with heparin/chitosan were superior as compared with BMP-2 implanted together with type I collagen. Interestingly, the heparin/chitosan complex induced a small amount of bone also without BMP-2 added. The heparin/chitosan was completely absorbed after 4 weeks as determined by histologic evaluation, and a normal active bone formation was present. The freeze-dried formulations of the carriers demonstrated similar osteoinductive effects as the gels. CONCLUSIONS: An osteoinductive formula for clinical use is needed for general bone reconstruction. Heparin in complex with chitosan has the ability to stabilize or activate the growth factor in vivo and induce the generation of new bone in good yields.
Subject headings and genre
-
Absorbable Implants
-
Animals
-
Biocompatible Materials
-
Biopsy
-
Needle
-
Bone Morphogenetic Proteins
-
pharmacology
-
Chitosan
-
pharmacology
-
Disease Models
-
Animal
-
Drug Carriers
-
Drug Delivery Systems
-
Heparin
-
pharmacology
-
Immunohistochemistry
-
Implants
-
Experimental
-
Male
-
Osteogenesis
-
drug effects
-
physiology
-
Random Allocation
-
Rats
-
Rats
-
Sprague-Dawley
-
Sensitivity and Specificity
-
Transforming Growth Factor beta
-
pharmacology
Added entries (persons, corporate bodies, meetings, titles ...)
-
Veltheim, Riikka
(author)
-
Arnander, ClaesKarolinska Institutet
(author)
-
Docherty-Skogh, Ann-Charlott
(author)
-
Westermark, Anders
(author)
-
Ohlsson, Claes,1965Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine(Swepub:gu)xohlcl
(author)
-
Adolfsson, Lars
(author)
-
Larm, Olle
(author)
-
Karolinska InstitutetInstitutionen för medicin, avdelningen för invärtesmedicin
(creator_code:org_t)
Related titles
-
In:Plastic and reconstructive surgery121:6, s. 1920-81529-4242
Internet link
Find in a library
To the university's database